NASDAQ:ACERAcer Therapeutics Stock Price, Forecast & News

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ACER shares have decreased by 3.6% and is now trading at $3.26. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acer Therapeutics.

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Acer Therapeutics.

Acer Therapeutics Inc (NASDAQ:ACER) issued its quarterly earnings data on Thursday, May, 14th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.09. View Acer Therapeutics' earnings history.

5 brokers have issued 1-year target prices for Acer Therapeutics' stock. Their forecasts range from $9.00 to $48.00. On average, they anticipate Acer Therapeutics' share price to reach $22.33 in the next year. This suggests a possible upside of 585.1% from the stock's current price. View analysts' price targets for Acer Therapeutics.

News articles about ACER stock have been trending somewhat negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Acer Therapeutics earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutAcer Therapeutics.

Acer Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 449,900 shares, an increase of 7.3% from the April 30th total of 419,400 shares. Based on an average trading volume of 85,800 shares, the short-interest ratio is presently 5.2 days. Currently, 9.0% of the company's shares are short sold. View Acer Therapeutics' Current Options Chain.

Some companies that are related to Acer Therapeutics include SUMMIT THERAPEU/S (SMMT), Savara (SVRA), GlycoMimetics (GLYC), Axovant Gene Therapies (AXGT), AVEO Pharmaceuticals (AVEO), Helix Biopharma (HBPCF), Theratechnologies (THERF), OASMIA PHARMACE/ADR (OASM), InflaRx (LUMO), Checkpoint Therapeutics (CKPT), Catabasis Pharmaceuticals (CATB), Galmed Pharmaceuticals (GLMD), ESSA Pharma (EPIX), Cyclerion Therapeutics (CYCN) and Recro Pharma (REPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Amarin (AMRN), Anavex Life Sciences (AVXL), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Arena Pharmaceuticals (ARNA) and Crispr Therapeutics (CRSP).

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (1.35%), Federated Hermes Inc. (0.89%), Parametric Portfolio Associates LLC (0.71%), Bank of New York Mellon Corp (0.21%) and WINTON GROUP Ltd (0.16%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View institutional ownership trends for Acer Therapeutics.

ACER stock was sold by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC, and WINTON GROUP Ltd. View insider buying and selling activity for Acer Therapeutics.

ACER stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., State Street Corp, and Bank of New York Mellon Corp. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm, and Steve Aselage. View insider buying and selling activity for Acer Therapeutics.

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $3.26.

Acer Therapeutics has a market capitalization of $33.42 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.

The official website for Acer Therapeutics is www.acertx.com.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]